Market Research Logo

Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update

Summary

Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Guardant Health Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Guardant Health Inc Company Overview
Guardant Health Inc Company Snapshot
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc – Pipeline Analysis Overview
Guardant Health Inc - Key Facts
Guardant Health Inc - Major Products and Services
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Pipeline Products Overview
Anti-RSP03 Antibody Based Blood Test
Anti-RSP03 Antibody Based Blood Test Product Overview
Gene-Based Test - Lung Cancer
Gene-Based Test - Lung Cancer Product Overview
GUARDANT360
GUARDANT360 Product Overview
GUARDANT360 Clinical Trial
Guardant360 CDx Test - Tepotinib
Guardant360 CDx Test - Tepotinib Product Overview
Guardant360 Companion Diagnostic Assay - Glesatinib
Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
Guardant Health Inc - Key Competitors
Guardant Health Inc - Key Employees
Guardant Health Inc - Locations And Subsidiaries
Head Office
Recent Developments
Guardant Health Inc, Recent Developments
Jul 19, 2018: New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients
Jul 18, 2018: Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit
Jul 12, 2018: Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications
Jul 12, 2018: Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer
May 23, 2018: Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications
Apr 26, 2018: Guardant Health Publishes Extensive Validation of Guardant360 Assay Comprising Largest-Published Blood-Tissue Comparison
Apr 13, 2018: Guardant Health to Present Validation Data for the GuardantOMNI assay
Mar 19, 2018: Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients
Mar 13, 2018: SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood
Mar 12, 2018: Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Indication
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc, Key Facts
Guardant Health Inc, Major Products and Services
Guardant Health Inc Number of Pipeline Products by Development Stage
Guardant Health Inc Pipeline Products Summary by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Ongoing Clinical Trials Summary
Anti-RSP03 Antibody Based Blood Test - Product Status
Anti-RSP03 Antibody Based Blood Test - Product Description
Gene-Based Test - Lung Cancer - Product Status
Gene-Based Test - Lung Cancer - Product Description
GUARDANT360 - Product Status
GUARDANT360 - Product Description
GUARDANT360 - A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies
GUARDANT360 - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection
GUARDANT360 - Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer
GUARDANT360 - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
GUARDANT360 - Noninvasive versus Invasive Lung Evaluation
GUARDANT360 - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial
Guardant360 CDx Test - Tepotinib - Product Status
Guardant360 CDx Test - Tepotinib - Product Description
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
Guardant Health Inc, Key Employees
Glossary
List of Figures
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report